December 21, 2022 Preliminary outcome in AlzeCure Pharma’s rights issue – Oversubscribed to 128 percent
June 29, 2022 Positive data from the clinical phase I MAD study with AlzeCure’s Alzheimer’s project NeuroRestore ACD856
April 13, 2022 AlzeCure’s rights issue is registered and the trading in Paid Subscription Shares ceases
April 11, 2022 AlzeCure carries out a set-off issue in connection with ACD440 entering phase II and Acturum Life investing in the company
